 Connection
Thomas Jensen to Middle Aged
This is a "connection" page, showing publications Thomas Jensen has written about Middle Aged.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.095 |
|
|
|
-
Shah SJ, Sharma K, Borlaug BA, Butler J, Davies M, Kitzman DW, Petrie MC, Verma S, Patel S, Chinnakondepalli KM, Einfeldt MN, Jensen TJ, Rasmussen S, Asleh R, Ben-Gal T, Kosiborod MN. Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials. Eur Heart J. 2024 Sep 14; 45(35):3254-3269.
Score: 0.012
-
Verma S, Butler J, Borlaug BA, Davies MJ, Kitzman DW, Petrie MC, Shah SJ, Jensen TJ, Rasmussen S, Rönnbäck C, Merkely B, O'Keefe E, Kosiborod MN. Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program. J Am Coll Cardiol. 2024 Oct 22; 84(17):1603-1614.
Score: 0.012
-
Petrie MC, Borlaug BA, Butler J, Davies MJ, Kitzman DW, Shah SJ, Verma S, Jensen TJ, Einfeldt MN, Liisberg K, Perna E, Sharma K, Ezekowitz JA, Fu M, Melenovský V, Ito H, Lelonek M, Kosiborod MN. Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program. J Am Coll Cardiol. 2024 Jul 02; 84(1):27-40.
Score: 0.012
-
Jensen TJ, Haarbo J, Pehrson SM, Thomsen B. Impact of premature atrial contractions in atrial fibrillation. Pacing Clin Electrophysiol. 2004 Apr; 27(4):447-52.
Score: 0.012
-
Crowley MJ, McGuire DK, Alexopoulos AS, Jensen TJ, Rasmussen S, Saevereid HA, Verma S, Buse JB. Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial. Diabetes Care. 2020 09; 43(9):e108-e110.
Score: 0.009
-
Nauck MA, Jensen TJ, Rosenkilde C, Calanna S, Buse JB. Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial. Diabetes Care. 2018 08; 41(8):1663-1671.
Score: 0.008
-
Ahrén B, Hirsch IB, Pieber TR, Mathieu C, Gómez-Peralta F, Hansen TK, Philotheou A, Birch S, Christiansen E, Jensen TJ, Buse JB. Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial. Diabetes Care. 2016 Oct; 39(10):1693-701.
Score: 0.007
-
van den Brink W, Strang J, Gual A, Sørensen P, Jensen TJ, Mann K. Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme. Expert Opin Drug Saf. 2015 Apr; 14(4):495-504.
Score: 0.006
-
Verhamme P, Pakola S, Jensen TJ, Berggren K, Sonesson E, Saint-Remy JM, Balchen T, Belmans A, Cahillane G, Stassen JM, Peerlinck K, Glazer S, Jacquemin M. Tolerability and pharmacokinetics of TB-402 in healthy male volunteers. Clin Ther. 2010 Jun; 32(6):1205-20.
Score: 0.005
-
Nielsen AL, Larsen TM, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Astrup A. [The effect of tesofensine on body weight and body composition in obese subjects--secondary publication]. Ugeskr Laeger. 2009 Oct 05; 171(41):2974-7.
Score: 0.004
-
Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008 11 29; 372(9653):1906-1913.
Score: 0.004
-
Bloch Thomsen PE, Joergensen RM, Kanters JK, Jensen TJ, Haarbo J, Hagemann A, Vestergaard A, Saermark K. Phase 2 reentry in man. Heart Rhythm. 2005 Aug; 2(8):797-803.
Score: 0.003
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|